Subcutaneous Testosterone Pellet Implant (Testopel®) Therapy for Men with Testosterone Deficiency Syndrome: A Single‐Site Retrospective Safety Analysis

Testosterone replacement with long‐acting Testopel pellets had a lower rate of infection (0.3%, 1/292 procedures) as compared with historical data from the Organon testosterone pellet (1.4-6.8%). Additionally, the rate of pellet extrusion was substantially lower (0.3%, 1/292 procedures) as compared with historical data (8.5-12%). None of the patients who complied with post‐implant procedure instructions experienced infection or pellet extrusion. Patient satisfaction was high and serum hormone values were improved. The low infection and extrusion rates observed may have been the result of the manufacturing process, which results in small, smooth‐surfaced pellets; the absence of foreign material within the pellet packaging; and/or differences in the surgical implantation technique used. Though Testopel pellets have been used in the United States for several decades, more research is needed to document their safety and efficacy. Cavender RK, and Fairall M. Subcutaneous testosterone pellet implant (Testopel®) therapy for men with testosterone deficiency syndrome: A single‐site retrospective safety analysis.